The C-terminal HSP90 inhibitor NCT-58 kills trastuzumab-resistant

β-Escin overcomes trastuzumab resistance in HER2-positive breast

Biomolecules, Free Full-Text

PDF) In Silico Discovery and Optimisation of a Novel Structural

Following the design path of isoform-selective Hsp90 inhibitors

PDF) A novel HSP90 inhibitor SL-145 suppresses metastatic triple

Characterization of p95HER2/611CTF-positive breast cancers and

Emerging insights into mechanisms of trastuzumab resistance in

New ruthenium-xanthoxylin complex eliminates colorectal cancer

Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab

New ruthenium-xanthoxylin complex eliminates colorectal cancer

PDF) In Silico Discovery and Optimisation of a Novel Structural

NCT-58 (CAS Number: 2411429-33-7)